ClarIDHy trial reports a small improvement in progression-free survival
The phase III trial confirms that targeting isocitrate dehydrogenase 1 mutations in cholangiocarcinoma is a promising strategy, but debate is open on whether results are clinically meaningful. In view of encouraging results in the treatment…
Read More
